VF
LYEL icon

Virtu Financial’s Lyell Immunopharma LYEL Stock Holding History

Virtu Financial’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-759
Closed -$29K – 1791
2023
Q4 		$29K Buy
+759
New +$27.3K ﹤0.01% 1261
2022
Q2 		– Sell
-1,860
Closed -$188K – 1856
2022
Q1 		$188K Buy
+1,860
New +$225K 0.01% 800

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial's LYEL Position: Q1 2024 in Review

Virtu Financial sold out of Lyell Immunopharma (LYEL) in Q1 2024, closing a stake of 759 shares — an estimated $29K sold.

Virtu Financial first reported a position in LYEL in Q1 2022 and held it in 2 quarters. The position peaked at $188K in Q1 2022. 127 funds tracked by Wall St. Rank hold LYEL as of Q1 2024.

  • Virtu Financial reported no remaining Lyell Immunopharma position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 759 Lyell Immunopharma shares in Q1 2024, an estimated $29K.
  • Virtu Financial first reported a position in Lyell Immunopharma in Q1 2022 and held it in 2 quarters.
  • Virtu Financial's Lyell Immunopharma position peaked at $188K in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.